Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
on sky news atm.
£20m in cash, £20m historic revenues, outlook v positive, cash flow neutral, more investment ahead from own resources. Big market to expand into with market-leading service. Hard to value but we all like growth, especially when from own resources.
Still looking cheap!
Proof of the pudding arrives. Congrats to the team for all their long hard work.
"DIACEUTICS TO BECOME FOURTH NORTHERN IRISH COMPANY LISTED ON LONDON STOCK EXCHANGE
RONAN LEONARD MARCH 18, 2019
Diaceutics plc, a revenue-generating, and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry, today announces that it is seeking a listing on the AIM Market of the London Stock Exchange. This will make Diaceutics the fourth Northern Irish company currently listed on the London Stock Exchange. The company is expected to have a market capitalisation on admission of approximately £53M. ..."
https://irishtechnews.ie/diaceutics-to-become-fourth-northern-irish-company-listed-on-london-stock-exchange/
Rockpool Acquisitions (ROC) is a main-listed cash shell, which may be of interest to investors seeking other Northern Ireland investments to DXRX:-
"A listed acquisition vehicle seeking opportunities in Northern Ireland.
Northern Ireland has a good availability of high quality, often internationally-focused, companies. Despite having an estimated 70,000 registered businesses, there are only two other publicly-listed companies predominantly based in Northern Ireland and Rockpool believes that more Northern Ireland businesses could benefit from the ability to tap into deeper pools of capital which access to the public markets provides.
With extensive knowledge and experience of the Northern Ireland market, the directors are seeking to identify and acquire a highly ambitious, Northern Ireland-based company that is focused on significant growth, and provide it with that access, helping that company meet its aspirations and full potential. Target companies will have a valuation of up to £20m."
http://rockpoolacquisitions.plc.uk/about-rockpool/
Rockpool Acquisitions (ROC) has a current market cap. of just £604K., at 4.75p.
Whereas the company has about £950K. cash, and extremely low cashburn.
ROC's large discount at the moment to its cash, despite this extremely low cashburn, looks like a temporary discrepancy - and one that is gradually being addressed by ROC's s.p. rise, as the market wakes up to the opportunity.
Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m.
Watch the video here: https://www.piworld.co.uk/company-videos/diaceutics-dxrx-full-year-2021-results-presentation-march-2022/
Or listen to the podcast here: https://piworld.podbean.com/e/diaceutics-dxrx-full-year-2021-results-presentation-march-2022/
In case you missed it, we have a recording from our webinar with Diaceutics on the 22nd September. See: https://www.sharesoc.org/seminar/sharesoc-webinar-with-diaceutics-plc-dxrx-22-september-2021/
Last chance to register for our webinar with Diaceutics PLC on Wednesday. Peter Keeling (CEO & Founder) and Philip White (CFO) will be giving the latest updates: https://www.sharesoc.org/events/sharesoc-webinar-with-diaceutics-plc-dxrx22-september-2021/
research-tree.com/companies/uk/biotechnology/diaceutics-plc/research/capital-access-group/diaceutics-initiation-note/23_2021091403175810086
We have today initiated coverage of Diaceutics plc, which has developed the world’s first all-parties marketplace platform (“DXRX”) that allows its clients, pharmaceutical companies, to review and connect with the laboratories and diagnostic companies needed to aid in the development, roll out, & uptake of the diagnostics which enable patient selection for the Pharmas’ Precision Medicines. Key to the investment case is that DXRX is now a heavily invested and scalable platform, with 70%-80% incremental gross margins and a relatively fixed cost base, operating in a high growth industry. It should therefore benefit from material operating leverage as top line growth returns post-pandemic, and we expect margins to grow significantly. You can read it here, or contact us to discuss it with the analyst.
Please find the link for the full announcement here:
https://*********************/companies/uk/biotechnology/diaceutics-plc/research/capital-access-group/diaceutics-initiation-note/23_2021091403175810086
We are hosting a webinar with Diaceutics PLC (DXRX) on the 22nd September, which may be of interest to shareholders or potential investors. Peter Keeling (CEO & Founder) and Philip White (CFO) will provide the latest updates: https://www.sharesoc.org/events/sharesoc-webinar-with-diaceutics-plc-dxrx22-september-2021/
Last year there was a brief trading statement with the AGM. Not this year. Related to change in advisor? So, next news a pre-close in mid -June. Although I didn’t buy in last year’s placing you’d expect those who paid top dollar before the September profit warning to be somewhat interested.
But ... I should still say thank you to Cenkos for introducing Diaceutics to retail investors like me a few years ago at one of those private investor conferences. Assuming things pan out as expected. Ofc.
A good thing moving up from U.K.-centric Cenkos to Stifel Nicolaus . They have a lot of US linkage and given our target markets it should be very helpful.
Strongly in the close, even on small - as I type.
Seems like things going pretty well here. Did the raise last year go to the wrong, impatient, people?
Pretty decent presentation here today:
https://www.investormeetcompany.com/
Seems like they have c.£10m revenues now but talked of a market worth £2-3bn for their market leading product. Gross margins are enormous and open pretty fixed. Valuation is rich based in current numbers, obviously, but DXRX just starting up and profits could be very impressive pretty quickly.
I've been holding Diaceutics since May 2020, its been a rocky ride but I'm glad I didn't offload my stake back in September. Comfortably in the blue now. Nice to see today's update and that the pandemic has not had the severe adverse impact on business the Board had initially anticipated ... good work on their part.
Excited to see where DXRX goes in the coming months. Good luck all investors :-)
obviously very bad luck that the profit warning came after the big capital raise and the positive July trading statement, and I would be feeling massively p'd off if I'd bought into the cap raise, but probably nothing more than bad luck even if quite a sudden turnaround in near term fortunes
....back to the top of the ride..
https://youtu.be/vWW2SzoAXMo
multi million dollar partnership with BioReference laboratories?
https://www.businesswire.com/news/home/20170424005689/en/Diaceutics-Signs-Multi-Million-Dollar-Partnership-BioReference-Laboratories-Improve
Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.
In response to the COVID-19 global pandemic, BioReference has completed the following to help support patients, providers and government agencies:
Launched nationwide availability of a Real-Time Reverse Transcription Polymerase Chain Reaction (Real-Time RT-PCR) assay to aid healthcare providers in quickly and efficiently diagnosing patients.
Increased laboratory testing capacity to ensure patients and providers have greater access to testing – currently can accommodate in excess of 20,000 COVID-19 tests per day.
Collaborated with the New York State Department of Health and Governor Andrew M. Cuomo to provide testing for the first public drive-through testing facility on the East Coast, located in New Rochelle, NY, the epicenter for the New York State outbreak. Additional satellite testing sites to be set-up in the coming weeks. Read the Governor’s Office statement here.
Collaborated with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide coronavirus disease 2019 (COVID-19) testing to patients within the more than 70 care locations across the city’s five boroughs.
Collaborated with the State of New Jersey to provide COVID-19 testing across the state, including access at the first five NJ drive-through testing facilities in the counties of Burlington, Essex, Hudson, Ocean and Union. Read the press release here.
Collaborated with the City of Detroit to provide COVID-19 testing at drive-through locations for residents by appointment.
Collaborated with the City of Miami to provide COVID-19 testing for Miami residents by appointment, and collaborated with Larkin Community Hospital to offer drive-through testing centers in South Florida, Hialeah and Hollywood, FL.
Announced continued prioritization of COVID-19 testing for hospital inpatients and critically ill patients around the country, with almost 200,000 patients tested to date.
More: https://www.bioreference.com/coronavirus
Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.
https://www.diaceutics.com/covid19-oncology-impact-tracker/
Diaceutics Chief Executive is giving a talk at the Growth and Innovation Forum 2020 lets see how investors like the company.